Published in Br J Cancer on May 01, 1999
Protective role of Puralpha to cisplatin. Cancer Biol Ther (2008) 1.44
Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res (2009) 0.96
Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res (2013) 0.84
A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair Deficiencies. Cancer Res (2016) 0.75
Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. Biotechniques (1990) 5.02
Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res (1994) 3.63
An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A (1993) 3.07
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci (1995) 2.63
Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A (1996) 2.57
Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (1993) 2.57
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci (1995) 2.36
Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res (1995) 2.35
DNA damage tolerance, mismatch repair and genome instability. Bioessays (1994) 2.23
Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res (1995) 2.17
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A (1994) 2.12
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem (1996) 2.01
Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res (1997) 1.96
Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol Cell Biol (1997) 1.79
Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry (1988) 1.76
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest (1991) 1.62
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. J Clin Invest (1996) 1.49
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol (1996) 1.42
Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem (1991) 1.32
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res (1988) 1.23
DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry (1995) 1.18
DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry (1989) 1.18
Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J Biol Chem (1993) 1.04
The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation. Mutat Res (1991) 0.84
Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J Cell Biochem (1994) 0.83
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
The idiopathic hypereosinophilic syndrome. Blood (1994) 4.65
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Recommendations of the German Association of Urogynecology on functional sonography of the lower female urinary tract. Int Urogynecol J Pelvic Floor Dysfunct (1996) 2.78
Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature (1994) 2.71
Transaxillary minithoracotomy versus video-assisted thoracic surgery for spontaneous pneumothorax. Ann Thorac Surg (1996) 2.65
Oxymetry deep in tissues with low-frequency electron paramagnetic resonance. Proc Natl Acad Sci U S A (1994) 2.53
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29
Host-parasite relationships in experimental airborne tuberculosis. II. Reproducible infection by means of an inoculum preserved at -70 C. J Bacteriol (1967) 2.29
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol (2001) 2.20
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol (1992) 2.10
Overexpression of metallothionein confers resistance to anticancer drugs. Science (1988) 2.03
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res (1981) 1.91
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Immediate reconstruction of the perineal wound with gracilis muscle flaps following abdominoperineal resection and intraoperative radiation therapy for recurrent carcinoma of the rectum. Ann Surg Oncol (1999) 1.88
Studies of morphology and immunofluorescence of Pneumocystis carinii. Proc Soc Exp Biol Med (1972) 1.82
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer (2003) 1.80
Crystal structure of NAD(+)-dependent DNA ligase: modular architecture and functional implications. EMBO J (2000) 1.78
Molecular cloning and expression of a complementary DNA for inositol 1,4,5-trisphosphate 3-kinase. Science (1990) 1.70
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68
Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A (1993) 1.63
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res (1997) 1.62
Needle thoracic sympathectomy for essential hyperhidrosis: intermediate-term follow-up. Ann Thorac Surg (2000) 1.60
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
Attempts at prophylaxis for murine Pneumocystis carinii pneumonitis. Curr Ther Res Clin Exp (1973) 1.57
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
Phylogenetic analysis of swine influenza viruses recently isolated in Korea. Virus Genes (2008) 1.52
Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol (1993) 1.52
Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction. IEEE Trans Med Imaging (2007) 1.51
Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost (2013) 1.50
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr (1973) 1.49
Arthroscopic one-piece excision technique for the treatment of symptomatic lateral discoid meniscus. Arthroscopy (1996) 1.48
Greater hemodynamic instability with histidine-tryptophan-ketoglutarate solution than University of Wisconsin solution during the reperfusion period in living donor liver transplantation. Transplant Proc (2008) 1.48
Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid). Nephrol Dial Transplant (1999) 1.48
Influence of type of carbohydrate on atherosclerosis in baboons fed semipurified diets plus 0.1% cholesterol. Am J Clin Nutr (1980) 1.47
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Intraaortic balloon rupture: a possible means of prevention. Ann Thorac Surg (1994) 1.45
Hospital mortality under surgical care. Ann R Coll Surg Engl (2011) 1.45
Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A (2001) 1.43
Retracted A phase I-II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies. Int J Radiat Oncol Biol Phys (1989) 1.43
Circulating immunoglobulin complexes in Wegener's granulomatosis. Am J Med (1976) 1.43
The porcine and lagomorph septal cartilages: models for tissue engineering and morphologic cartilage research. Am J Rhinol (2001) 1.42
Thioredoxin-linked "thiol peroxidase" from periplasmic space of Escherichia coli. J Biol Chem (1995) 1.40
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
Nerve growth factor stimulates phosphorylation of phospholipase C-gamma in PC12 cells. J Biol Chem (1991) 1.38
Removals of hydrogen peroxide and hydroxyl radical by thiol-specific antioxidant protein as a possible role in vivo. Biochem Biophys Res Commun (1993) 1.38
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36
Effective patient care in the pediatric ambulatory setting: a study of the acute care clinic. Pediatrics (1969) 1.32
Analysis of the yeast arginine methyltransferase Hmt1p/Rmt1p and its in vivo function. Cofactor binding and substrate interactions. J Biol Chem (2000) 1.31
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol (2001) 1.28
Direct evidence that the protein kinase catalytic subunit mediates the effects of cAMP on tyrosine aminotransferase synthesis. J Biol Chem (1983) 1.28
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer (2001) 1.26
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 1.26
Global analysis of the human gastric epithelial transcriptome altered by Helicobacter pylori eradication in vivo. Gut (2006) 1.25
The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol (1980) 1.24
Ethnopharmacology and systems biology: a perfect holistic match. J Ethnopharmacol (2005) 1.23
Quality of life research in oncology. Past achievements and future priorities. Cancer (1991) 1.23
Biological resurfacing of full-thickness defects in patellar articular cartilage of the rabbit. Investigation of autogenous periosteal grafts subjected to continuous passive motion. J Bone Joint Surg Br (1992) 1.23
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res (1987) 1.23
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res (1983) 1.23
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck (1992) 1.22
Measurement of differences in pO2 in response to perfluorocarbon/carbogen in FSa and NFSa murine fibrosarcomas with low-frequency electron paramagnetic resonance oximetry. Radiat Res (1996) 1.21
A case of retroperitoneal lipoleiomyoma. J Korean Med Sci (2001) 1.21
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol (1998) 1.20
New cold-adapted lipase from Photobacterium lipolyticum sp. nov. that is closely related to filamentous fungal lipases. Appl Microbiol Biotechnol (2005) 1.19
The GlnD and GlnK homologues of Streptomyces coelicolor A3(2) are functionally dissimilar to their nitrogen regulatory system counterparts from enteric bacteria. Mol Microbiol (2002) 1.18
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res (2001) 1.18
Gene expression signatures associated with the resistance to imatinib. Leukemia (2006) 1.17